Abstract:Abstract Background The selection and prioritization of drug targets is a central problem in drug discovery. Computational approaches can leverage the growing number of large-scale human genomics and proteomics data to make in-silico target identification, reducing the cost and the time needed. Results We developed a machine learning approach to score proteins to generate a druggability score of novel targets. In our model we incorporated 70 protein features which included properties derived from the sequence, features characterizing protein functions as well as network properties derived from the protein-protein interaction network. The advantage of this approach is that it is unbiased and even less studied proteins with limited information about their function can score well as most of the features are independent of the accumulated literature. We build models on a training set which consist of targets with approved drugs and a negative set of non-drug targets. The machine learning techniques help to identify the most important combination of features differentiating validated targets from non-targets. We validated our predictions on an independent set of clinical trial drug targets, achieving a high accuracy characterized by an Area Under the Curve (AUC) of 0.89. Our most predictive features included biological function of proteins, network centrality measures, protein essentiality, tissue specificity, localization and solvent accessibility. Our predictions, based on a small set of 102 validated oncology targets, recovered the majority of known drug targets and identifies a novel set of proteins as drug target candidates. Conclusions We developed a machine learning approach to prioritize proteins according to their similarity to approved drug targets. We have shown that the method proposed is highly predictive on a validation dataset consisting of 277 targets of clinical trial drug confirming that our computational approach is an efficient and cost-effective tool for drug target discovery and prioritization. Our predictions were based on oncology targets and cancer relevant biological functions, resulting in significantly higher scores for targets of oncology clinical trial drugs compared to the scores of targets of trial drugs for other indications. Our approach can be used to make indication specific drug-target prediction by combining generic druggability features with indication specific biological functions.

Prediction of Drug Targets for Specific Diseases Leveraging Gene Perturbation Data: A Machine Learning Approach

Learning the Drug Target-Likeness of A Protein

In silico prediction of novel therapeutic targets using gene–disease association data

Machine learning prediction of oncology drug targets based on protein and network properties

Improved Prediction Of Drug-Target Interactions Based On Ensemble Learning With Fuzzy Local Ternary Pattern

A machine learning approach to drug repositioning based on drug expression profiles: Applications to schizophrenia and depression/anxiety disorders

Prediction of drug efficacy from transcriptional profiles with deep learning

An Ensemble Learning-Based Method for Inferring Drug-Target Interactions Combining Protein Sequences and Drug Fingerprints

Novel Neural Network Approach to Predict Drug-Target Interactions Based on Drug Side Effects and Genome-Wide Association Studies

A New Approach to Drug Repurposing with Two-Stage Prediction, Machine Learning, and Unsupervised Clustering of Gene Expression

Expanding drug targets for 112 chronic diseases using a machine learning-assisted genetic priority score

Prediction of drug effectiveness in rheumatoid arthritis patients based on machine learning algorithms

Machine Learning Prediction of On/Off Target-driven Clinical Adverse Events

Attention-based approach to predict drug-target interactions across seven target superfamilies

A Systematic Prediction Of Multiple Drug-Target Interactions From Chemical, Genomic, And Pharmacological Data

Drug target, class level, and PathFX pathway information share utility for machine learning prediction of common drug-induced side effects

Prediction of Drug Class and Adverse Sideeffects Based on Induced Gene Expressionprofiles - a Feasability Study

Machine Learning in Modeling Disease Trajectory and Treatment Outcomes: An Emerging Enabler for Model‐Informed Precision Medicine

Machine learning in the development of targeting microRNAs in human disease

Predicting tumor response to drugs based on gene-expression biomarkers of sensitivity learned from cancer cell lines

Prediction of drug-target interactions for drug repositioning only based on genomic expression similarity